Trials / Completed
CompletedNCT01021358
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-263 (Navitoclax)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single dose, open-label, single or multiple center study to determine the interaction of ketoconazole with ABT-263 in approximately 12 subjects with cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-263 | Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole. |
| DRUG | Ketoconazole | Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole. |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2010-10-01
- First posted
- 2009-11-30
- Last updated
- 2010-12-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01021358. Inclusion in this directory is not an endorsement.